
|Videos|November 13, 2020
Imaging and biopsy practices in active surveillance for low-risk prostate cancer
Author(s)Urology Times staff
Christopher P. Evans, MD, and J. Brantley Thrasher, MD, conclude an in-depth discussion on active surveillance in men with low-risk prostate cancer.
Advertisement
In the second installment of J. Brantley Thrasher, MD’s interview with Christopher P. Evans, MD, regarding active surveillance for low-risk prostate cancer, Evans discusses his imaging and biopsy regimens, how he handles PI-RADS 3 lesions, and more. Evans is professor and chair of the Department of Urologic Surgery at the University of California, Davis, School of Medicine. Thrasher is executive director of the American Board of Urology, Charlottesville, Virginia.
Advertisement
Related to this article

The phase 1/2 CELC-G-201 study found preliminary antitumor activity and manageable toxicity with gedatolisib plus darolutamide in metastatic castration-resistant prostate cancer.

Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.

Longer-term findings from the phase 2 ARACOG study suggest differences in objectively measured cognitive function between ARPIs.

Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.

Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.

Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.

Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Advertisement
Advertisement
Trending on Urology Times
1
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
Adding perioperative pembrolizumab to chemotherapy does not improve EFS in MIBC
4
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
5

